


**eFigure 1: Participant Enrollment at Each Site**



**eTable 1: Participant Characteristics and Clinical Profiles by Age Group**

	<12 Years of Age (n=17)	12-30 Years of Age (n=20)	p-value
	Mean, Standard Deviation		
Follow-Up Duration (years)	4.42, 2.88	3.54, 1.95	0.29
	<12 Years of Age (n=17)	12-30 Years of Age (n=20)	p-value
	Number, Percentage		
Female	10, 59	16, 80	0.14
White Race	5, 29	10, 50	0.19
Seizures	12, 71	17, 85	0.22
Tumor Present	5, 29	6, 30	1.00
Immunotherapy#			
First-Line Only	8, 47	3, 15	
First- and Second-Line	9, 53	17, 85	<b>0.02</b>
Intensive Care Unit Required	6, 35	13, 65	0.09
mRS at Admission			
mRS 0-2	1, 6	1, 5	1.00
mRS 3-5	16, 94	19, 95	

#First-Line Treatment = steroids, plasma exchange, and/or IV immunoglobulin. Second-Line Treatment = rituximab and/or cyclophosphamide.  
Abbreviations: mRS = modified Rankin Scale

**eTable 2: Clinical and Patient Factors Associated with Adaptive Function\* (n=40)**

	ABAS-3 General Adaptive Composite Standard Score		
	Mean	Standard Deviation	p-value <sup>^</sup>
Male	79.64	18.84	<b>0.006</b>
Female	97.34	16.51	
White	96.45	17.63	0.18
Not White	88.5	19.4	
Seizures	88.4	18.8	0.47
No Seizures	93.6	18.8	
Tumor	94.5	15.2	0.63
No Tumor	91.5	20.4	
Intensive Care Unit Required	90.0	16.8	0.42
Intensive Care Unit Not Required	94.9	20.7	
First-Line Immunotherapy <sup>#</sup>	95.3	20.5	0.59
Second-Line Immunotherapy <sup>#</sup>	91.5	20.5	
Time From Symptom Onset to Study Enrollment	N/A	N/A	0.10


\*Adaptive Function as measured by the Adaptive Behavior Assessment System, Third Edition General Adaptive Composite standard score

<sup>#</sup>First-line treatment defined as steroids, plasma exchange, and/or IV immunoglobulin. Second-line treatment defined as rituximab and/or cyclophosphamide.

<sup>^</sup>Two-sided t-tests were used for categorical independent variables. Simple regression was used for continuous independent variable (i.e., Time From Symptom Onset to Study Enrollment).

Abbreviations: ABAS-3 = Adaptive Behavior Assessment System, Third Edition

**eFigure 2: Categorical Age at Symptom Onset and Distribution of Adaptive Function (Total and Domain) Scores**



**eTable 3: Adaptive Function (Total and Domain Scores) by Age of Symptom Onset (n=35)**

ABAS-3 Standard Scores	0 to 11 years (n=17)		12 to 30 years (n=18)		p-value
	Mean	Standard Deviation	Mean	Standard Deviation	
General Adaptive Composite	87	20	99	14	<b>0.049</b>
Conceptual Domain					
Communication	87	17	97	13	0.080
Functional Academics	88	21	102	13	<b>0.026</b>
Self-Direction	89	19	98	14	0.160
Social Domain					
Leisure	90	19	96	15	0.268
Social	94	18	102	12	0.118
Practical Domain					
Community Use	90	20	98	14	0.142
Home Living	90	20	99	17	0.137
Health and Safety	92	19	104	15	<b>0.038</b>
Self-Care	89	19	105	14	<b>0.007</b>

Abbreviations: ABAS-3 = Adaptive Behavior Assessment System, Third Edition

**eTable 4: Age at Symptom Onset and Other Outcomes at Study Enrollment**

**a. Neurologic Disability (n=36; modified Rankin Scale (mRS))**

	mRS 0-2 (n=31)		mRS 3-6 (n=5)		p-value
	Mean	Standard Deviation	Mean	Standard Deviation	
Age at Symptom Onset (years)	14.4	7.9	9.0	8.0	0.17
Follow-Up Duration (years)	3.8	2.0	4.8	4.6	0.43

	mRS 0-2 (n=31)		mRS 3-6 (n=5)		p-value
	Number		Number		
0 to 11 years (n=17)	13		4		0.17
12 to 30 years (n=19)	18		1		

**b. Neurobehavioral Features (n=34)**

***Fatigue***

	Fatigue		No Fatigue		p-value
	Mean	Standard Deviation	Mean	Standard Deviation	
Age at Symptom Onset (years)	20.3	13.3	18.4	18.8	0.77
Follow-Up Duration (years)	3.6	1.8	4.1	2.6	.62

	Fatigue		No Fatigue		p-value
	Number		Number		
0 to 11 years (n=17)	2		15		0.06
12 to 30 years (n=17)	8		9		

***Emotional Lability***

	Emotional Lability		No Emotional Lability		p-value
	Mean	Standard Deviation	Mean	Standard Deviation	
Age at Symptom Onset (years)	24.5	19.6	13.6	13.2	<b>0.04</b>
Follow-Up Duration (years)	4.3	2.7	3.6	2.0	0.34

	Emotional Lability		No Emotional Lability		p-value
	Number		Number		
0 to 11 years (n=17)	6		11		0.49
12 to 30 years (n=17)	9		8		

**Short-Term Memory Difficulties**

	Short-Term Memory Difficulties		No Short-Term Memory Difficulties		p-value
	Mean	Standard Deviation	Mean	Standard Deviation	
Age at Symptom Onset (years)	23.7	18.8	15.3	15.4	0.13
Follow-Up Duration (years)	3.5	1.9	4.3	2.7	0.29

	Short-Term Memory Difficulties		No Short-Term Memory Difficulties		p-value
	Number	Number	Number	Number	
0 to 11 years (n=17)	5	12	12	8	0.30
12 to 30 years (n=17)	9	8	8	9	

**Concentration Difficulties**

	Concentration Difficulties		No Concentration Difficulties		p-value
	Mean	Standard Deviation	Mean	Standard Deviation	
Age at Symptom Onset (years)	16.1	13.7	21.0	19.4	0.39
Follow-Up Duration (years)	3.1	1.3	4.5	2.8	0.08

	Concentration Difficulties		No Concentration Difficulties		p-value
	Number	Number	Number	Number	
0 to 11 years (n=17)	7	10	10	7	1.00
12 to 30 years (n=17)	8	9	9	8	